The board of directors at AbbVie Inc. has announced a quarterly cash dividend of $1.64 per share. This dividend is scheduled for payment on August 15, 2025, to shareholders recorded by the close of business on July 15, 2025.
AbbVie has consistently increased its dividend since its inception in 2013, achieving a growth rate of 310 percent. The company is recognized as part of the S&P Dividend Aristocrats Index, which includes companies that have raised their dividends annually for at least 25 consecutive years.
AbbVie focuses on developing and delivering innovative medicines and solutions aimed at addressing serious health issues today while preparing for future medical challenges. The company's work spans several therapeutic areas such as immunology, oncology, neuroscience, and eye care. Additionally, AbbVie offers products and services within its Allergan Aesthetics portfolio.
For more details about AbbVie, visit their website or follow them on various social media platforms including LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube.
For media inquiries:
Gabby Tarbert - (224) 244-0111 - gabrielle.tarbert@abbvie.com
For investor inquiries:
Liz Shea - (847) 935-2211 - liz.shea@abbvie.com